Valeo Financial Advisors LLC Has $2.34 Million Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Valeo Financial Advisors LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 4,031 shares of the medical research company’s stock after purchasing an additional 247 shares during the period. Valeo Financial Advisors LLC’s holdings in Thermo Fisher Scientific were worth $2,343,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of the company. Sivia Capital Partners LLC lifted its stake in Thermo Fisher Scientific by 28.3% in the 1st quarter. Sivia Capital Partners LLC now owns 634 shares of the medical research company’s stock valued at $368,000 after purchasing an additional 140 shares during the last quarter. SeaCrest Wealth Management LLC lifted its position in Thermo Fisher Scientific by 2.5% during the first quarter. SeaCrest Wealth Management LLC now owns 1,654 shares of the medical research company’s stock worth $961,000 after acquiring an additional 40 shares during the last quarter. Naviter Wealth LLC lifted its position in Thermo Fisher Scientific by 54.4% during the first quarter. Naviter Wealth LLC now owns 3,433 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 1,210 shares during the last quarter. Quattro Financial Advisors LLC lifted its position in Thermo Fisher Scientific by 973.4% during the first quarter. Quattro Financial Advisors LLC now owns 5,700 shares of the medical research company’s stock worth $3,313,000 after acquiring an additional 5,169 shares during the last quarter. Finally, Eagle Ridge Investment Management lifted its position in Thermo Fisher Scientific by 39.2% during the first quarter. Eagle Ridge Investment Management now owns 1,249 shares of the medical research company’s stock worth $726,000 after acquiring an additional 352 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TMO. Jefferies Financial Group restated a “buy” rating and set a $650.00 price objective (up from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Deutsche Bank Aktiengesellschaft raised their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. HSBC raised their target price on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Robert W. Baird lowered their target price on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. Finally, JPMorgan Chase & Co. raised their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $606.47.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $535.56 on Thursday. The firm’s fifty day moving average is $573.89 and its 200-day moving average is $563.61. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The firm has a market cap of $204.43 billion, a PE ratio of 34.35, a price-to-earnings-growth ratio of 2.49 and a beta of 0.77. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be issued a dividend of $0.39 per share. The ex-dividend date is Friday, June 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,000 shares of company stock worth $12,532,780. Company insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.